SCHEMBL2928075

SCHEMBL2928075

COC(=O)c1cc(F)cc([N+](=O)[O-])c1NC(C)=O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.44
LMNA P02545 3/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
NPSR1 Q6W5P4 2/20 0.44
POLB P06746 2/20 0.44
GALR2 O43603 1/20 0.44
MITF O75030 1/20 0.44
HSP90AA1 P07900 1/20 0.44
HPGD P15428 1/20 0.44
XBP1 P17861 1/20 0.44
CCR6 P51684 1/20 0.44
MAPT P10636 4/20 0.42
GAA P10253 3/20 0.42
KDM4E B2RXH2 2/20 0.42
PDGFRB P09619 1/20 0.41
FGFR1 P11362 1/20 0.41
PDGFRA P16234 1/20 0.41
FLT1 P17948 1/20 0.41
FGFR3 P22607 1/20 0.41
KDR P35968 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9064586 0.86 MAPT (0.44) ALDH1A1LMNASMN1; SMN2NPSR1POLB
SCHEMBL3449671 0.81 MAPT (0.47) ALDH1A1LMNASMN1; SMN2NPSR1POLB
SCHEMBL913705 0.81 PDGFRB (0.46) ALDH1A1MAPTKDM4EPDGFRBFGFR1
SCHEMBL2046728 0.81 PDGFRB (0.49) ALDH1A1LMNASMN1; SMN2NPSR1POLB
SCHEMBL4022732 0.81 PDGFRB (0.46) ALDH1A1MAPTKDM4EPDGFRBFGFR1
SCHEMBL31159174 0.81 PDGFRB (0.49) ALDH1A1LMNASMN1; SMN2NPSR1POLB
SCHEMBL29722774 0.80 ALDH1A1 (0.48) ALDH1A1LMNASMN1; SMN2NPSR1POLB
SCHEMBL3300905 0.80 ALDH1A1 (0.48) ALDH1A1LMNASMN1; SMN2NPSR1POLB
SCHEMBL29858635 0.80 TTR (0.50) ALDH1A1LMNAHPGDMAPTKDM4E
SCHEMBL205671 0.80 TTR (0.50) ALDH1A1LMNAHPGDMAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1910314-B1 BENZIMIDAZOLE DERIVATIVES FOR TREATMENT OF INFLAMMATORY DISEASES NOVARTIS AG (CH) 2010-09-15 EP disclosed
US-20080306064-A1 Benzimidazole Derivatives BROWN LYNDON NIGEL 2008-12-11 US disclosed
EP-1910314-A1 BENZIMIDAZOLE DERIVATIVES FOR TREATMENT OF INFLAMMATORY DISEASES Novartis AG (CH) 2008-04-16 EP disclosed
WO-2007009774-A1 BENZIMIDAZOLE DERIVATIVES FOR TREATMENT OF INFLAMMATORY DISEASES NOVARTIS AG (CH) 2007-01-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080306064-A1 Benzimidazole Derivatives PPARG, PPARD, BRD4 ALDH1A1 767/4885LMNA 1938/4885SMN1; SMN2 4540/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.